On Tuesday, Baird reiterated its Outperform rating on Spyre (NASDAQ: SYRE) shares, currently trading at $27.65, with a consistent price target of $65.00. With a market capitalization of $1.6 billion, the clinical-stage biotech company has initiated Phase 1 trials for its SPY002 (TL1A) drug candidate.
The commencement of these trials marks a significant step forward in the company's clinical development pipeline. According to InvestingPro, the stock has shown considerable volatility, with analyst targets ranging from $40 to $71.
Spyre has recently reviewed preliminary data from its SPY001 (α4β7) trials, which indicated a longer than anticipated half-life for the drug. Encouraged by these findings, the company has launched two Phase 1 trials to evaluate SPY002.
Initial results from these studies are expected to be available in the second quarter of 2025. The company maintains a strong liquidity position, with InvestingPro data showing a healthy current ratio of 7.32 and more cash than debt on its balance sheet.
The company has outlined its strategy to advance one of the SPY002 candidates into Phase 2 trials for ulcerative colitis. Moreover, a separate Phase 2 study for an indication outside of inflammatory bowel disease (IBD) is slated for next year.
Spyre is also preparing for a Phase 1 study of another drug candidate, SPY003 (IL-23), which is anticipated to commence in the first quarter of 2025 with healthy volunteers.
The analyst from Baird has expressed confidence in Spyre's clinical progress, stating, "Phase 1 SPY002 studies now underway." The firm's endorsement of the Outperform rating underscores its positive outlook on Spyre's potential in the biopharmaceutical sector, particularly as the company advances its drug candidates through the clinical trial process.
In other recent news, Spyre Therapeutics has initiated Phase 1 trials for two potential treatments for inflammatory bowel disease. The trials will evaluate the safety and pharmacokinetics of the SPY002 molecules. The company also recently secured $230 million in financing, boosting its cash position.
In addition to these developments, Spyre has launched a public offering of up to $200 million and revised its net loss per share calculations for the fiscal year 2023 and the first three quarters of 2024 due to identified errors.
Further, Spyre has reported promising Phase 1 results for its drug candidate SPY001, which targets inflammatory bowel disease. The drug was well-tolerated in trials and exhibited a half-life over 90 days, suggesting less frequent dosing could be possible. The company plans to initiate a Phase 2 trial in mid-2025.
Stifel, an analyst firm, has raised the stock's price target for Spyre Therapeutics to $71 from $54, following the release of positive trial data for SPY001. In other company news, Spyre Therapeutics has presented encouraging data for SPY003, which has a longer half-life than its competitor Skyrizi, potentially allowing for less frequent dosing schedules for patients. These are some of the recent developments in the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.